Description: Anti-CD20 Monoclonal Antibody
CSA NA – FDA Approved – REMS (N) – Can Ship
How Does It Work
Ocrelizumab, Ocrevus is a recombinant humanized IgG monoclonal antibody directed against B-cells which express the cell surface antigen CD20 which is present on both pre-B and mature B lymphocytes. B-cells are thought to be heavily involved in the course of multiple sclerosis via a variety of mechanisms.
Indications For Use
Multiple sclerosis, relapsing or primary progressive
Before starting Ocrelizumab, Ocrevus make sure your physician is aware of any allergies or medications you currently take if you have an active infection, an active malignancy, are immunocompromised, are pregnant, or breastfeeding. Ocrelizumab, Ocrevus use has been associated with rare but serious adverse events such as hepatitis B reactivation, increased risk of herpes infection, immunoglobulin reduction, increased risk of infection, infusion reactions, increased risk of malignancy, progressive multifocal leukoencephalopathy.
IV: 300 mg on day 1, followed by 300 mg 2 weeks later then subsequent doses of 600 mg are administered once every 6 months
Pharmacist Tips On Using
How to Take: Administer through a dedicated IV line using a 0.2 or 0.22-micron in-line filter. Premedicate with methylprednisolone 30 minutes prior to each infusion, and an antihistamine 30 to 60 minutes prior to each infusion. Monitor for infusion reactions during the infusion and observe for at least one hour after the infusion is complete. If an infusion reaction occurs, interrupt infusion, discontinue or decrease the rate, depending on the severity of the reaction. If a dose is missed, administer as soon as possible (do not wait until the next scheduled dose), then adjust the dosing schedule to administer the next sequential dose 6 months after the missed dose was administered. Administer live-attenuated or live immunizations at least 4 weeks and non-live immunizations at least 2 weeks prior to treatment initiation. Immunization with live-attenuated or live vaccines is not recommended during treatment or after discontinuation until B-cell repletion. Non-live vaccines may be administered; however, consideration should be given to evaluating the immune response. Store intact vials at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light. Solutions diluted for infusion should be used immediately, however may be stored for up to 24 hours refrigerated and 8 hours at room temperature.
You Need to Avoid: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance so avoid starting any new medications without consulting the prescriber. Do not freeze or shake the product.
Skin infection, decreased neutrophils, decreased serum immunoglobulins, infection, upper respiratory tract infection, infusion-related reaction
Note this is not a complete list of side effects, only the most common
Frequently Asked Questions
What do I do if side effects are intolerable?
If side effects are causing a lot of distress speak to your physician as soon as possible to discuss options.